Northwest Biotherapeutics Announces the Completion of Financing on a Favorable Terms for Approximately $8 Million

Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company has completed a financing on favorable terms for approximately $8 million.  The Company anticipates that this financing will help maintain the Company's momentum, and will provide some prudent protection in the midst of the current global economic uncertainties.  The financing also further broadens the lock-up of warrants that the Company has been building. An additional approximately 75.5 million existing warrants, outstanding prior to this financing and held by investors in this financing, have been suspended until December 15, 2020 as part of this financing.  These warrant suspensions were compensated on a similar basis as the warrant suspensions previously reported.  In addition, all new warrants in this financing are suspended until December 15, 2020. As the Company approaches the read-out of its Phase III trial of DCVax®-L for Glioblastoma brain cancer, the Company is working with a growing team of technical experts and regulatory advisers on various readiness preparations, including manufacturing related preparations.  This financing will help the Company maintain its momentum in these very important activities.